Immune Checkpoint Inhibitor-Associated Colits and Hepatitis

被引：79

作者：

Reddy, Haritha G. ^{[1
]}

Schneider, Bryan J. ^{[1
]}

Tai, Andrew W. ^{[2
,3
,4
]}

机构：

[1] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA

[4] VA Ann Arbor Healthcare Syst, Med Serv, Ann Arbor, MI 48105 USA

来源：

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY | 2018年 / 9卷

基金：

美国国家卫生研究院;

关键词：

ADVANCED MELANOMA; ADVERSE EVENTS; IPILIMUMAB; CANCER; NIVOLUMAB; IMMUNOTHERAPY; MONOTHERAPY; BLOCKADE; FEATURES; THERAPY;

D O I：

10.1038/s41424-018-0049-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that target downregulators of the anti-cancer immune response: cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand PD-L1. ICPIs are now approved for the treatment of a wide array of malignancies, with rates of durable responses in the metastatic setting far exceeding what would be expected from conventional chemotherapy. ICPIs have also been associated with rare but serious immune-related adverse events due to over-activation of the immune system that can affect any organ, including the gastrointestinal tract and liver. As the use of ICPIs in oncology continues to increase, ICPI-associated colitis and hepatitis will be encountered frequently by gastroenterologists and hepatologists. This review will focus on the diagnosis and management of ICPI-associated colitis and hepatitis. We will also compare these ICPI-related toxicities with sporadic inflammatory bowel disease and autoimmune liver disease.

引用

页数：9

共 37 条

[11] Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury [J].

Doherty, Gary Joseph ;

Duckworth, Adam M. ;

Davies, Susan E. ;

Mells, George F. ;

Brais, Rebecca ;

Harden, Susan V. ;

Parkinson, Christine A. ;

Corrie, Pippa G. .

ESMO OPEN, 2017, 2 (04)

[12] Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis [J].

Dubin, Krista ;

Callahan, Margaret K. ;

Ren, Boyu ;

Khanin, Raya ;

Viale, Agnes ;

Ling, Lilan ;

No, Daniel ;

Gobourne, Asia ;

Littmann, Eric ;

Huttenhower, Curtis ;

Pamer, Eric G. ;

Wolchok, Jedd D. .

NATURE COMMUNICATIONS, 2016, 7

[13] Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management [J].

Foppen, Marnix H. Geukes ;

Rozeman, Elisa A. ;

van Wilpe, Sandra ;

Postma, Cindy ;

Snaebjornsson, Petur ;

van Thienen, Johannes V. ;

van Leerdam, Monique E. ;

van den Heuvel, Michel ;

Blank, Christian U. ;

van Dieren, Jolanda ;

Haanen, John B. A. G. .

ESMO OPEN, 2018, 3 (01)

[14] Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases [J].

Ghabril, Marwan ;

Bonkovsky, Herbert L. ;

Kum, Clarissa ;

Davern, Tim ;

Hayashi, Paul H. ;

Kleiner, David E. ;

Serrano, Jose ;

Rochon, Jim ;

Fontana, Robert J. ;

Bonacini, Maurizio .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (05) :558-+

[15] Systematic review: colitis associated with anti-CTLA-4 therapy [J].

Gupta, A. ;

De Felice, K. M. ;

Loftus, E. V., Jr. ;

Khanna, S. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (04) :406-417

[16] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Haanen, J. B. A. G. ;

Carbonnel, F. ;

Robert, C. ;

Kerr, K. M. ;

Peters, S. ;

Larkin, J. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2017, 28 :119-142

Horvat, Troy Z. ;

Adel, Nelly G. ;

Thu-Oanh Dung ;

Momtaz, Parisa ;

Postow, Michael A. ;

Callahan, Margaret K. ;

Carvajal, Richard D. ;

Dickson, Mark A. ;

D'Angelo, Sandra P. ;

Woo, Kaitlin M. ;

Panageas, Katherine S. ;

Wolchok, Jedd D. ;

Chapman, Paul B. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3193-+

[18]

Ibrahim RA, 2011, J CLIN ONCOL S, V29, P8583, DOI DOI 10.1200/jco.2011.29.15_suppl.8583

[19] Ipilimumab-associated Hepatitis Clinicopathologic Characterization in a Series of 11 Cases [J].

Johncilla, Melanie ;

Misdraji, Joseph ;

Pratt, Daniel S. ;

Agoston, Agoston T. ;

Lauwers, Gregory Y. ;

Srivastava, Amitabh ;

Doyle, Leona A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (08) :1075-1084

[20] Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders [J].

Johnson, Douglas B. ;

Sullivan, Ryan J. ;

Ott, Patrick A. ;

Carlino, Matteo S. ;

Khushalani, Nikhil I. ;

Ye, Fei ;

Guminski, Alexander ;

Puzanov, Igor ;

Lawrence, Donald P. ;

Buchbinder, Elizabeth I. ;

Mudigonda, Tejaswi ;

Spencer, Kristen ;

Bender, Carolin ;

Lee, Jenny ;

Kaufman, Howard L. ;

Menzies, Alexander M. ;

Hassel, Jessica C. ;

Mehnert, Janice M. ;

Sosman, Jeffrey A. ;

Long, Georgina V. ;

Clark, Joseph I. .

JAMA ONCOLOGY, 2016, 2 (02) :234-240

← 1 2 3 4 →